To support preclinical and clinical development programs, ERBC conducts PK-PD and metabolism studies on pharmaceuticals and biotechnology based products.

Conducted in a broad range of administration routes, dosing regimens and animal species, these studies are managed by senior scientists with deep expertise in biology, pharmacology, data analytics and regulatory.

Pharmacokinetic - bioavailability

• Species: rat, mouse, rabbit, dog, minipig, marmoset
• All administration routes
• Analysis of biological samples (plasma, urine, tissues…)

Pharmacodynamic in vivo and in vitro

• Deep expertise in human recombinant proteins, notably GSCF, hGH and EPO (in vivo)

In vitro metabolism

• Evaluation of metabolism using liver metabolic fractions (S9, microsomes)
• Evaluation of metabolism using hepatocytes
• Metabolite profiling, identification and quantification
• CYP phenotyping assay
• CYP induction in human hepatocytes
• CYP inhibition in human liver microsomes
• Time dependent CYP inhibition in human liver microsomes

Skin Penetration Study

• In vitro Skin Absorption (OECD 428) 

Histochemical and immunohistochemical determinations in tissues

• Cytochrome p450
• Glutathion S-transferase
• γ-Glutamyl transpeptidase
• Cytochrome oxidase
• Adenosine triphosphatase
• Glucose-6-phosphate dehydrogenase